Mid
V
VNDAAI Stock Diagnostic Report
Vanda gets EMA orphan drug designation for imsidolimab in GPP
[MISTRAL] Vanda Pharmaceuticals' imsidolimab has received EMA orphan drug designation as a treatment for GPP, attracting attention.
View Source Article ↗
AI CATALYST SCORE75 / 100Score computed by Sentinel V12
REFERENCE PRICENot measuredReference entry price at analysis time
+ANALYSIS HISTORY
VNDA Analysis History (Last 30 Days)